CancerCompass message board discussion started by Gdpawel on 8/16/2007 http://www.cancercompass.com/message-board/message/all,15370,0.htm Wed, 08 Oct 2008 00:00:00 GMT Wed, 08 Oct 2008 00:00:00 GMT http://backend.userland.com/rss RSS.NET: http://www.rssdotnet.com/ With relapsed, platinum-resistant ovarian cancer, every clinical trial in history has just shown a 10-12 month median survival in this setting. However, background data (680 fresh surgical specimens) for the design of a clinical trial to determine the efficacy of assay-directed therapy of platinum-resistant ovarian cancer, submitted to the 2003 Society of Gynecologic Oncology meeting, had a 27 month median survival and a fair number of long-term survivors (2004-AB-171-SGO). All specimens were tested with two separate Medicare-approved cell culture assays (DISC and MTT) having cell-death endpoints.American Journal of Obstetrics and Gynecology, 2003, 189, number 5: 1301-1307Functional profiling with cell culture assayshttp://cancerfocus.net/forum/showthread.php?t=253 " target="_blank" rel="nofollow">http://cancerfocus.net/forum/showthread.php?t=253 , 2003, 189, number 5: 1301-1307Functional profiling with cell culture assayshttp://cancerfocus.net/forum/showthread.php?t=253 " target="_blank" rel="nofollow">http://cancerfocus.net/forum/showthread.php?t=253 Gdpawel Thu, 16 Aug 2007 00:00:00 GMT